Eli Lilly and Company (NYSE: LLY), a United States-based pharmaceutical company, announced on Thursday that its board of directors has named Gabrielle Sulzberger as its new director, effective 25 January 2021.

Sulzberger will serve on both the company's Audit Committee and Ethics and Compliance Committee.

Sulzberger serves as a strategic advisor to Two Sigma Impact. She has held the position of a general partner of Rustic Canyon/Fontis Partners LP. She was also a principal of several private equity funds during her 30 plus-years of experience in financial services and chief financial officer of several public and private companies. Presently, Sulzberger is also a member of the board of directors for various companies including MasterCard Incorporated, Brixmor Property Group Inc, Cerevel Therapeutics Holdings Inc, and several other private companies and philanthropic organisations. She has held the position of chairman of the board of Whole Foods and audit committee chair for Whole Foods.